Cargando…

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

The causative agent of the ongoing pandemic in the world is SARS-CoV-2. The research on SARS-CoV-2 has progressed with lightning speed on various fronts, including clinical research and treatment, virology, epidemiology, drug development, and vaccine research. Recent studies reported that sera from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muthumani, Kar, Xu, Ziyang, Jeong, Moonsup, Maslow, Joel N., Kalyanaraman, Vaniambadi S., Srinivasan, Alagarsamy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248284/ https://www.ncbi.nlm.nih.gov/pubmed/34230895 http://dx.doi.org/10.1186/s41231-021-00093-2

Ejemplares similares

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing
por: Mahalingam, Sundarasamy, et al.
Publicado: (2021)

Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?
por: Anguela, Xavier M., et al.
Publicado: (2019)

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
por: Johansson, Maria U., et al.
Publicado: (2023)

Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?
por: Nasrallah, Gheyath K.
Publicado: (2022)

The gift of preexisting immunity for developing an alternative vaccine strategy
por: Tran, Kim A., et al.
Publicado: (2023)

Preexisting Antibodies to an F(ab′)(2) Antibody Therapeutic and Novel Method for Immunogenicity Assessment
por: Ruppel, Jane, et al.
Publicado: (2016)

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals
por: Cheedarla, Narayanaiah, et al.
Publicado: (2017)

Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?
por: Bowsher, Ronald R., et al.
Publicado: (2020)

A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: Potential impact on CTL epitopes
por: Srinivasan, Alagarsamy, et al.
Publicado: (2008)

Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein
por: Bordoloi, Devivasha, et al.
Publicado: (2021)

Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
por: Chung, Christopher, et al.
Publicado: (2023)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Combination anti‐HIV antibodies to achieve antiretroviral therapy‐free virological suppression in infected individuals
por: Rai, M. Ali, et al.
Publicado: (2022)

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
por: Ng, Kevin W., et al.
Publicado: (2020)

On the importance of population-based serological surveys of SARS-CoV-2 without overlooking their inherent uncertainties
por: Kritsotakis, Evangelos I.
Publicado: (2020)

Serological Number for Characterization of Circulating Antibodies
por: Palermo, Andrea, et al.
Publicado: (2019)

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
por: Mendell, Jerry R., et al.
Publicado: (2022)

Cognitive decline among older adults: A hidden preexisting condition and its role in ‘brain‐at‐risk’ surgical patients
por: Brenna, Connor T. A., et al.
Publicado: (2021)

Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs)
por: Perales-Puchalt, Alfredo, et al.
Publicado: (2019)

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
por: Lee, Eun-Ju, et al.
Publicado: (2022)

Developing Monoclonal Antibodies for Immunohistochemistry
por: Cordell, Jacqueline
Publicado: (2022)

Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis
por: Yamada, Takahiro, et al.
Publicado: (2019)

Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
por: Kudchodkar, Sagar B., et al.
Publicado: (2018)

A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
por: Majdoubi, Abdelilah, et al.
Publicado: (2021)

Maturation of arteriovenous fistulas in patients with and without preexisting hemodialysis catheters
por: Wongmahisorn, Yuthapong
Publicado: (2019)

Genetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease
por: Jing, Wenjiang, et al.
Publicado: (2019)

Quantitative serological antibody testing for suspected neuroborreliosis
por: Schneider, Christian, et al.
Publicado: (2020)

SEROLOGIC TESTS FOR DETECTION OF ANTIBODY TO RODENT VIRUSES
por: Smith, Abigail L.
Publicado: (1986)

Antinuclear antibodies defining autoimmunity pathways
por: Tan, Eng M
Publicado: (2014)

The Road to Toxin-Targeted Therapeutic Antibodies
por: Kozel, Thomas R.
Publicado: (2014)

The Yin and Yang of ADCC-Mediating Antibodies
por: Robert-Guroff, Marjorie
Publicado: (2016)

Inhalable antibodies for the treatment of COVID-19
por: Yang, Zhenlin, et al.
Publicado: (2022)

The Combination of Dupilumab with Other Monoclonal Antibodies
por: Gisondi, P., et al.
Publicado: (2022)

Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease
por: Maslow, Joel N., et al.
Publicado: (2019)

Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection
por: Achan, Jane, et al.
Publicado: (2020)

Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France
por: Zedan, Hadeel T., et al.
Publicado: (2021)

New Paths in Human Cancer Serology
por: Old, Lloyd J., et al.
Publicado: (1998)

New Antibody Weapons against an Old Foe
por: Benach, Jorge L.
Publicado: (2011)

Influenza Virus Resistance to Human Neutralizing Antibodies
por: Crowe, James E.
Publicado: (2012)

Bromodomains shake the hegemony of pan-acetyl antibodies
por: Champleboux, Morgane, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o2iao8ecicmmupj3l9un79da9b